However, in pathologies associated with upregulated GRK2, such as cardiovascular, renal, metabolic, cancer, and neurodegenerative diseases, enhanced receptor desensitization is not always desirable (2, 3). This evidence concerns the gene GRK2 and neurodegenerative disease.